Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
Kroeze LI, de Voer RM, Kamping EJ, von Rhein D, Jansen EAM, Hermsen MJW, Barberis MCP, Botling J, Garrido-Martin EM, Haller F, Lacroix L, Maes B, Merkelbach-Bruse S, Pestinger V, Pfarr N, Stenzinger A, van den Heuvel MM, Grünberg K, Ligtenberg MJL. Kroeze LI, et al. Among authors: pfarr n. J Mol Diagn. 2020 Jun;22(6):757-769. doi: 10.1016/j.jmoldx.2020.02.009. Epub 2020 Mar 20. J Mol Diagn. 2020. PMID: 32205293 Free article.
Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer.
Saini M, Schmidleitner L, Moreno HD, Donato E, Falcone M, Bartsch JM, Klein C, Vogel V, Würth R, Pfarr N, Espinet E, Lehmann M, Königshoff M, Reitberger M, Haas S, Graf E, Schwarzmayr T, Strom TM, Spaich S, Sütterlin M, Schneeweiss A, Weichert W, Schotta G, Reichert M, Aceto N, Sprick MR, Trumpp A, Scheel CH. Saini M, et al. Among authors: pfarr n. Cell Rep. 2023 Jun 27;42(6):112533. doi: 10.1016/j.celrep.2023.112533. Epub 2023 May 30. Cell Rep. 2023. PMID: 37257449 Free article.
Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.
Kriegsmann M, Endris V, Wolf T, Pfarr N, Stenzinger A, Loibl S, Denkert C, Schneeweiss A, Budczies J, Sinn P, Weichert W. Kriegsmann M, et al. Among authors: pfarr n. Oncotarget. 2014 Oct 30;5(20):9952-65. doi: 10.18632/oncotarget.2481. Oncotarget. 2014. PMID: 25296970 Free PMC article.
118 results